Lupin surges on forming Strategic Partnership with MSD

Lupin Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500257 | NSE: LUPIN

18 Jul 2013 Evaluate

Lupin is currently trading at Rs. 895.00, up by 21.45 points or 2.46% from its previous closing of Rs. 873.55 on the BSE.

The scrip opened at Rs. 879.50 and has touched a high and low of Rs. 904.95 and Rs. 879.10 respectively. So far 1, 04,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 904.95 on 18-Jul-2013 and a 52 week low of Rs. 540.15 on 11-Oct-2012.

Last one week high and low of the scrip stood at Rs. 895.00 and Rs. 859.65 respectively. The current market cap of the company is Rs. 40,062 crore.

The promoters holding in the company stood at 46.81% while Institutions and Non-Institutions held 43.07% and 10.12% respectively.

Pharma Major Lupin (Lupin) and MSD, one of the world's leading players in 23-valent Pneumococcal Polysaccharide Vaccines category has formed an India-specific strategic partnership. Within the scope of the partnership, Lupin will have a non-exclusive license to market, promote and distribute MSD's 23-valent Pneumococcal Polysaccharide Vaccine under a different brand name in India.

Pneumococcal polysaccharide vaccine (PPV) addresses the need of prevention of pneumococcal disease in India with its proven efficacy and broader coverage-PPV23 provides broader coverage and has proven efficacy for prevention of pneumococcal diseases which help addresses the need of prevention of pneumococcal disease in India, based on the clinical experience since last 3 decades, PPV23 has good safety profile.

Recent India focused study showed that more than 80% of invasive serotype groups of Streptococcus pneumoniae causing disease in the elderly in India are included in the formulation of PPV 23 which makes this vaccine relevant from India perspective and PPV23 is recommended worldwide for prevention of pneumococcal diseases in adults by leading medical societies like Advisory committee on Immunization Practices, American Diabetes Association, American Thoracic society, Geriatric society of India etc.

Lupin Share Price

2273.65 -104.25 (-4.38%)

11-May-2026 14:18 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1873.00
Dr. Reddys Lab	1289.40
Cipla	1307.55
Zydus Lifesciences	953.55
Lupin	2273.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.